

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 June 2001 (14.06.2001)

PCT

(10) International Publication Number  
**WO 01/42281 A1**

(51) International Patent Classification<sup>7</sup>: C07K 7/04, 7/06, A61K 38/08

(21) International Application Number: PCT/CA00/01445

(22) International Filing Date: 6 December 2000 (06.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/455,483 6 December 1999 (06.12.1999) US

(71) Applicant (for all designated States except US): HÔPITAL SAINTE-JUSTINE [CA/CA]; 3175, Côte Sainte-Catherine, Montréal, Québec H3T 1C5 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PERI, Krishna, G. [CA/CA]; 3130 Toupin, St-Laurent, Québec H4K 1Y8 (CA). CHEMTOB, Sylvain [CA/CA]; 6885 Banting, Montréal, Québec H4W 1G1 (CA).

(74) Agents: CÔTÉ, France et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS FOR TREATING ABNORMALITIES IN GLOMERULAR FILTRATION, PATENT DUCTUS ARTERIOSUS AND OSTEOPOROSIS

(57) Abstract: The present invention relates to a composition of matter comprising novel prostaglandin E2 receptor antagonists, and their use in treatments for regulating the fluid filtration in the kidney, preventing bone mineral loss in osteoporosis and dental disease and additionally, closure of ductus arteriosus (DA) in premature infants or fetal animals. Additionally, the compositions include linear peptides, peptide analogs, and peptidomimetics.

WO 01/42281 A1

## COMPOSITIONS FOR TREATING ABNORMALITIES IN GLOMERULAR FILTRATION, PATENT DUCTUS ARTERIOSUS AND OSTEOPOROSIS

### BACKGROUND OF THE INVENTION

#### 5 (a) Field of the Invention

The invention relates to compounds and the use of novel peptide and peptidomimetic antagonists of a G protein coupled receptor, in treatments focused on regulating the fluid filtration in the kidney in case of acute renal failure, end stage renal disease, glomerulonephritis and other  
10 nephropathies, on decreasing resorption and bone mineral loss as in osteoporosis and dental diseases and additionally, closure of ductus arteriosus (DA) in premature infants or fetal animals.

#### (b) Description of Prior Art

Prostaglandins are derived from the oxygenation of arachidonic  
15 acid by prostaglandin (PG) synthases. Prostaglandins mediate a wide variety of physiological actions, such as vasomotricity, sleep/wake cycle, intestinal secretion, lipolysis, glomerular filtration, mast cell degranulation, neurotransmission, platelet aggregation, leuteolysis, myometrial contraction and labor, inflammation and arthritis, patent ductus arteriosus,  
20 cell growth and differentiation. Prostanoids mediate their actions through binding to distinct receptors which belong to the super family of rhodopsin-like seven transmembrane helical receptors. These receptors are coupled to heterotrimeric G-proteins comprising of  $\alpha$ ,  $\beta$  and  $\gamma$  subunits which, upon activation, elicit alterations in cell calcium, initiate phosphoinositide  
25 hydrolysis or promotion or repression of cyclic adenosine monophosphate synthesis.

Of the five pharmacologically-distinct prostanoid receptors for  $\text{PGE}_2$ ,  $\text{PGI}_2$ ,  $\text{PGD}_2$ ,  $\text{PGF}_{2\alpha}$  and  $\text{TxA}_2$ , four subtypes of  $\text{PGE}_2$  receptor are described (Ichikawa, et al. 1996). These are  $\text{EP}_1$ ,  $\text{EP}_2$ ,  $\text{EP}_3$  which has  
30 several splice variants and  $\text{EP}_4$ . Cloned human  $\text{EP}_4$  (also known as prostaglandin E2 receptor subtype  $\text{EP}_4$ ) is a 488 amino acid glycoprotein, linked to  $\text{G}_{\alpha s}$  and involved in stimulation of adenylate cyclase and cAMP

synthesis (Abramovitz, M. et al., US patent Nos. 5,759,789 and 5,605,814). EP<sub>4</sub> receptor is expressed at a high level in intestine, but at much lower levels in lung, kidney, thymus, uterus and brain (Bastien, Y. et al. 1994 *J. Biol. Chem.* **269** (16):11873-77). EP<sub>4</sub> is expressed in ductus arteriosus (Bhattacharya, M. et al. 1999. *Circulation.* **100**:1751-56). Paradoxically, EP<sub>4</sub> knock-out mice die after birth due to insufficient closure of ductus arteriosus (Nguyen, M. et al. 1997. *Nature.* **390**: 78-81; Segi, E. et al., 1998). Hence the mechanism of ductal patency and the role of EP<sub>4</sub> remain elusive.

PGE<sub>2</sub> is abundantly produced in kidney and is involved in the regulation of renal microcirculation, salt and water transport, renin release (Breyer, M. D. et al. 1998. *Kidney Int.* **54** (Suppl. 67): S88-94). All EP receptors have been shown to be regionally distributed in the kidney structures (Morath, R. et al. 1999. *J. Am. Soc. Nephrol.* **10**: 1851-60) and are associated with specific functions. All studies on the distribution of EP receptors in kidney showed that EP<sub>4</sub> receptor is uniquely expressed in glomeruli (Breyer, M. D. et al. 1996. *Am. J. Physiol.* **270**: F912-918; Morath, R., 1999), however the presence of this receptor in other structures of the nephron, such as collecting duct (Breyer, M.D., et al. 1996), the media of renal arteries and vasa recta (Morath, R. et al. 1999) is variously reported. EP<sub>4</sub> transcripts were also found in juxtaglomerular granule cells and is consistent with PGE<sub>2</sub>-induced cAMP synthesis in these cells; hence EP<sub>4</sub> may also play a role in renin secretion. Glomerular prostaglandins are thought to affect filtration (Schlondoff, D. et al. 1987. *Kidney Int.* **29**: 108-19) and renin release. PGE<sub>2</sub> increases cAMP levels in isolated glomeruli (Freidlander, G. et al., 1983. *Mol. Cell. Endocrinol.* **30**: 201-214). It is suggested that EP<sub>4</sub> receptor coupled to cAMP synthesis may regulate glomerular filtration (Sugimoto, Y. et al., 1994), though a direct demonstration of its role is lacking. Most importantly, there is no data in the literature on whether stimulation or antagonism of EP<sub>4</sub> receptor would result in increased glomerular filtration or how improving glomerular

filtration could have therapeutic benefits in acute renal disease end stage renal disease, glomerulonephritis and diabetic nephropathy.

Bones undergo continuous remodeling in which bone formation is carried out by osteoblasts and bone resorption is carried out by  
5 osteoclasts. These processes are controlled by several humoral factors such as parathyroid hormone, estradiol, vitamin D, cytokines, growth factors and prostaglandins. It is known that osteoclast induction by interleukin-1 (IL-1) is inhibited by aspirin-like drugs (Tai, H., et al., 1997. *Endocrinology*. 138: 2372-2379). PGE2 analogs with EP4 receptor  
10 agonistic activity promoted osteoclast formation in cocultures of mouse osteoblasts and bone marrow cells and similar experiments using cells from EP4-knockout mice resulted in reduced osteoclast formation, suggesting a role for EP4 receptor in osteoclastogenesis in mice (cited in Narumiya, S. et al. 1999. *Physiol. Rev.* 79: 1193-1226). Hence it is  
15 expected that EP4 antagonists would have therapeutic benefits in medical conditions such as osteoporosis, dental diseases and other diseases where bone loss is integral part of the disease process. Lack of selective antagonists to EP4 receptor hindered progress in this area of research; it is therefore one of the objects of the present invention to overcome one or  
20 more of these deficiencies in the art.

It would be desirable to be provided with a prostaglandin E2 receptor subtype EP4 receptor antagonist capable of inhibiting at least one functional consequence of said receptor activity.

It would be desirable to be provided with a method of use for  
25 such an antagonist in a suitable pharmaceutical formulation with the purpose of improving glomerular filtration and/or urine output of a patient while treating end stage renal disease glomerulonephritis, diabetic nephropathy or acute renal failure, or closing ductus arteriosus (DA) in a premature infant patient, or preventing further bone loss in osteoporosis,  
30 dental disease, and other medical conditions where bone loss is a problem.


In order to further the search for small molecule antagonists of EP4 receptor using highthroughput screening approaches, it is desirable to provide a bioassay or a kit in which appropriately labelled antagonist of EP4 receptor of the present invention could be used as a ligand.

5

### **SUMMARY OF THE INVENTION**

One aim of the present invention is to provide a peptidic or peptidomimetic form of a prostaglandin E2 receptor subtype EP4 antagonist capable of inhibiting at least one of the functional  
10 consequences the receptor activation

Another aim of the invention is to provide a compound which comprises a peptide of the following general formula:



wherein,

15 Y1 is attached to the N-terminus of the peptide and selected from the group consisting of a proton, a sequence of 1-3 amino acids, or a blocking group such as a carbamate group, an acyl group composed of a hydrophobic moiety such as cyclohexyl, phenyl, benzyl, short chain linear and branched alkyl groups of 1-8 carbons of which acetyl and benzoyl are  
20 examples;

R1 is selected from the group consisting of Val, Ala, Ile, Gln, Leu, or Arg;

R2 is selected from the group consisting of Ala, Ile, Phe, Arg, or Leu;

R3 is selected from the group consisting of Pro, Thr, Ser, Tyr, Leu, or Val;

R4 is selected from the group consisting of Met, Ala, Gly, Ser, Val, or Ile;

25 R5 is selected from the group consisting of Thr, Pro, Tyr, Leu, Gly, or Gln;

R6 is selected from the group consisting of is Val, Cys, Ile, Gly, Glu, or Ser;


R7 is selected from the group consisting of is Pro, Val, Cys, Leu, Glu or Asn;

30 R8 is selected from the group consisting of is Ser, Leu, Thr, or Ala

Z1 is attached to the carboxy-terminus of the peptide and selected from the group consisting of proton, NH<sub>2</sub>, 1-3 amino acids as well as arylalkyl amines such as benzylamine, phenylethylamine, phenylpropylamine, and aliphatic amines possessing short chain linear and branched alkyl groups of 1 to 8 carbons.

The invention also aims to provide a pharmaceutical composition containing a peptidic or peptidomimetic compound wherein said compound is capable of inhibiting at least one functional consequence of prostaglandin E2 receptor subtype EP4 activity.

As yet another objective is to disclose a compound wherein the compound comprises a peptide having a structural formula:



wherein:

Y2 is attached to the N-terminus of the peptide and selected from the group consisting of a proton, a sequence of 1-3 amino acids, or a blocking group such as a carbamate group, an acyl group composed of a hydrophobic moiety such as cyclohexyl, phenyl, benzyl, short chain linear and branched alkyl groups of 1-8 carbons of which acetyl and benzoyl are examples;

AA1 is selected from the group consisting of no residue, Ile, Leu, Phe and related alpha-amino acids possessing hydrophobic side-chains, arylalkyl amines such as benzylamine;

AA2 is selected from the group consisting of no residue, Leu, Ile, Phe and related alpha-amino acids possessing hydrophobic side-chains, arylalkyl amines such as benzylamine;

AA3 is selected from the group consisting of no residue, Ala, Ser, Thr and other related alpha amino acids possessing side chains containing hydroxyl or H-bond forming groups;

AA4 is selected from the group consisting of Ser, Thr, and related alpha-amino acids possessing side chains containing hydroxyl groups or H-bond forming groups;

AA5 is selected from the group consisting of Ala, Tyr, Phe, and other related alpha amino acids possessing side chains containing benzoyl and phenolic groups as well as arylalkyl amines such as benzylamine;

5 AA6 is selected from the group consisting of Glu, Gln, Asp, Asn, and related alpha amino acids possessing side chains containing charged or H-bond accepting groups;

AA7 is selected from the group consisting of no residue, Ala, Cys, Ser, Thr and related alpha-amino acids possessing side chains containing sulfhydryl, hydroxyl groups;

10 AA8 is selected from the group consisting of no residue, Ile, Ala, Leu, Phe and other alpha-amino acids possessing hydrophobic side-chains, as well as arylalkyl amines such as benzylamine, phenylethylamine, phenylpropylamine, and aliphatic amines possessing short chain linear and branched alkyl groups of 1 to 8 carbons;

15 Z2 is attached to the carboxy-terminus of the peptide and selected from the group consisting of proton,  $\text{NH}_2$ , 1-3 amino acids as well as arylalkyl amines such as benzylamine, phenylethylamine, phenylpropylamine, and aliphatic amines possessing short chain linear and branched alkyl groups of 1 to 8 carbons.

20 It is also the aim of the invention is to provide derivatives of the said compounds which may be synthetic polypeptides, those containing conservative substitutions of individual amino acids, peptidomimetics.

Another objective is to provide compounds which are capable of modulating the functional consequences of prostaglandin E2 receptor  
25 subtype EP4 in assays using cultured cells, tissues and animals.

It is also an aim of the present invention to provide a composition comprising an antagonist of the prostaglandin E2 receptor subtype EP4 in association with a pharmaceutically acceptable carrier.

30 Another aim of the present invention is to provide the use of a pharmaceutical composition containing a prostaglandin E2 receptor subtype EP4 antagonist for improving glomerular filtration and/or urine

output of a patient, treating end stage renal disease or acute renal failure, or closing ductus arteriosus (DA) in a premature infant patient.

Another aim of the present invention is to provide the use of a pharmaceutical composition containing a prostaglandin E2 receptor  
5 subtype EP4 antagonist for the treatment of osteoporosis.

It is another aim of the present invention to provide the use of a prostaglandin E2 receptor subtype EP4 antagonist in a bioassay and a kit that incorporates the use of the said antagonist for screening libraries of compounds.

10

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

Fig.1 illustrates the effects of PHG213 on the changes in ocular perfusion pressure in response to PGE<sub>2</sub>;

15 Fig.2 illustrates the effects of PHG213 on glomerular filtration rate and urinary volume in normal rats;

Fig.3 illustrates the effects of PHG213 on glomerular filtration rate and urinary volume in diabetic rats;

Fig. 4 illustrates the effects of PHG 213 on ductus arteriosus diameter in fetal sheep measured by Doppler-echocardiography; and

20 Fig. 5 illustrates the effect of PHG213 on osteoclastogenesis (TRAP+ cells) with human fetal spleen cells in coculture with fixed SaOS-2 cells.

#### **DETAILED DESCRIPTION OF THE INVENTION**

25 Prostanoid receptors are G protein coupled receptors whose natural ligands are the cyclooxygenase products of arachidonic acid, a C20:4 unsaturated fatty acid. No known ligands of these receptors are of peptidic in nature. Prostaglandin E2 binds many G protein-coupled receptor subtypes of which subtype EP4 is of particular importance in  
30 several pathologies. Specific antagonists of EP4 receptor are not available




nor is the validation of the functional role of this receptor un mammalian physiology.

An aim of the present invention is to address such deficiencies in the arts and provide a selective inhibitor of EP4 receptor.

5 A novel aspect of the present invention is that the described antagonists of prostaglandin E2 receptor subtype EP4 is peptidic in nature. Also provided herein is a structure of such an antagonist and the possible derivatives which may mimic the functional and structural features of said antagonist in assays involving cells, tissues and animals, as known to  
10 people skilled in the art.

Therefore a compound is provided which comprises a peptide of at least 8 amino acid of the following general formula,



15 wherein,

Y1 is attached to the N-terminus of the peptide and selected from the group consisting of a proton, a sequence of 1-3 amino acids, or a blocking group such as a carbamate group, an acyl group composed of a hydrophobic moiety such as cyclohexyl, phenyl, benzyl, short chain linear  
20 and branched alkyl groups of 1-8 carbons of which acetyl and benzoyl are examples;

R1 is selected from the group consisting of Val, Ala, Ile, Gln, Leu, or Arg;

R2 is selected from the group consisting of Ala, Ile, Phe, Arg, or Leu;

R3 is selected from the group consisting of Pro, Thr, Ser, Tyr, Leu, or Val;

25 R4 is selected from the group consisting of Met, Ala, Gly, Ser, Val, or Ile;

R5 is selected from the group consisting of Thr, Pro, Tyr, Leu, Gly, or Gln;

R6 is selected from the group consisting of is Val, Cys, Ile, Gly, Glu, or Ser;

30 R7 is selected from the group consisting of is Pro, Val, Cys, Leu, Glu or Asn;

R8 is selected from the group consisting of is Ser, Leu, Thr, or Ala;

Z1 is attached to the carboxy-terminus of the peptide and selected from the group consisting of proton, NH<sub>2</sub>, 1-3 amino acids as well as arylalkyl amines such as benzylamine, phenylethylamine, phenylpropylamine, and aliphatic amines possessing short chain linear and branched alkyl groups of 1 to 8 carbons.

In addition, a composition is also disclosed, wherein the composition comprises a peptide having the structure

Y2-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-Z2

wherein:

Y2 is attached to the N-terminus of the peptide and selected from the group consisting of a proton, a sequence of 1-3 amino acids, or a blocking group such as a carbamate group, an acyl group composed of a hydrophobic moiety such as cyclohexyl, phenyl, benzyl, short chain linear and branched alkyl groups of 1-8 carbons of which acetyl and benzoyl are examples;

AA1 is selected from the group consisting of no residue, Ile, Leu, Phe and related alpha-amino acids possessing hydrophobic side-chains, arylalkyl amines such as benzylamine;

AA2 is selected from the group consisting of no residue, Leu, Ile, Phe and related alpha-amino acids possessing hydrophobic side-chains, arylalkyl amines such as benzylamine;

AA3 is selected from the group consisting of no residue, Ala, Ser, Thr and other related alpha amino acids possessing side chains containing hydroxyl or H-bond forming groups;

AA4 is selected from the group consisting of Ser, Thr, and related alpha-amino acids possessing side chains containing hydroxyl groups or H-bond forming groups;

AA5 is selected from the group consisting of Ala, Tyr, Phe, and other related alpha amino acids possessing side chains containing benzoyl and phenolic groups as well as arylalkyl amines such as benzylamine;

AA6 is selected from the group consisting of Glu, Gln, Asp, Asn, and

related alpha amino acids possessing side chains containing charged or H-bond accepting groups ;

AA7 is selected from the group consisting of no residue, Ala, Cys, Ser, Thr and related alpha-amino acids possessing side chains containing  
5   sulfhydryl, hydroxyl groups;

AA8 is selected from the group consisting of no residue, Ile, Ala, Leu, Phe and other alpha-amino acids possessing hydrophobic side-chains, as well as arylalkyl amines such as benzylamine, phenylethylamine, phenylpropylamine, and aliphatic amines possessing short chain linear  
10   and branched alkyl groups of 1 to 8 carbons;

Z2 is attached to the carboxy-terminus of the peptide and selected from the group consisting of proton,  $\text{NH}_2$ , 1-3 amino acids as well as arylalkyl amines such as benzylamine, phenylethylamine, phenylpropylamine, and aliphatic amines possessing short chain linear and branched alkyl groups  
15   of 1 to 8 carbons.

The term "amino acid" as used herein includes both L and D isomers of the naturally occurring amino acids as well as other nonproteinaceous amino acids used in peptide chemistry to prepare synthetic analogs of peptides. Examples of naturally-occurring amino acids  
20   are glycine, alanine, valine, leucine, isoleucine, serine, threonine, etc. whereas non-naturally occurring amino acids are norleucine, norvaline, cyclohexyl alanine, biphenyl alanine, homophenyl alanine, naphthyl alanine, pyridyl alanine, phenyl alanines substituted at the ortho, para and meta positions with alkoxy, halogen or nitro groups etc. These compounds  
25   are known to persons versed in the art of peptide chemistry.

The term "polar amino acid" means any amino acid containing an uncharged residue but is relatively soluble in water.

The term "hydrophobic amino acid" means any amino acid containing an uncharged side chain which is insoluble in water.

30   The term "patient" denotes any animal, particularly, humans.

For the purpose of clarity, commonly accepted notations of amino

acids are given below:

Full Name	Three-Letter Code	One-Letter Code
Aspartic Acid	Asp	D
Glutamic Acid	Glu	E
Lysine	Lys	K
Arginine	Arg	R
Histidine	His	H
Tyrosine	Tyr	Y
Cysteine	Cys	C
Asparagine	Asn	N
Glutamine	Gln	Q
Serine	Ser	S
Threonine	Thr	T
Glycine	Gly	G
Alanine	Ala	A
Valine	Val	V
Leucine	Leu	L
Isoleucine	Ile	I
Methionine	Met	M
Proline	Pro	P
Phenylalanine	Phe	F
Tryptophan	Trp	W

- Peptidomimetics: It is well known in the art of drug design to identify a substitute compound that mimics the conformation of the peptide, hence reproduces its functional activity; at the same time avoiding the undesirable features of peptides, such as flexibility, protease-sensitivity, oxidizability of constituents, barrier impermeability and size. Such a compound that mimics the peptide is called a "peptidomimetic".
- 5

The methods of designing and synthesizing peptidomimetics are well known to people skilled in that art.

In designing peptidomimetics, people skilled in the arts analyze the structure of a given peptide by making conservative and nonconservative substitutions, deletions at each position of the amino acid and correlate such changes with alterations in physical or biological activity. For example, conservative amino acid changes may be made to the actual sequence of the peptide, which although they alter the primary sequence of the peptide, do not normally alter its function. Conservative amino acid substitutions typically include substitutions within the following groups:

glycine, alanine;  
valine, isoleucine, leucine;  
aspartic acid, glutamic acid;  
asparagine, glutamine;  
serine, threonine;  
lysine, arginine;  
phenylalanine, tyrosine.

Modifications (which do not normally alter primary sequence) include *in vivo*, or *in vitro* chemical derivatization of polypeptides, e.g., acetylation, or carboxylation.. Further modifications include attachment of polyethylene glycol molecules of various molecular weights (PEGylation) to improve the bioavailability, fatty acid modification to improve its barrier penetrability, and modifications by tissue-targeting antibodies or polypeptides, small molecules are also included herein.

Also included are polypeptides which have been modified using peptide chemistry so as to improve their resistance to proteolytic degradation or to optimize solubility properties or to render them more suitable as a therapeutic agent. Analogs of such polypeptides include those containing residues other than naturally occurring L-amino acids,

e.g., D-amino acids or non-naturally occurring synthetic amino acids, as known to persons skilled in the art of peptidomimetic chemistry.

Unless otherwise specified, all peptides and peptidomimetics used in this invention contained D-amino acids.

5 Furthermore, replacing blocks of amino acids with synthetic scaffolds, as practiced in case of beta turn mimetics, or use beta amino acids in place of natural amino acids are some of the practices in peptidomimetic chemistry.

Peptide synthesis: The synthesis of the peptides and  
10 peptidomimetic compounds described in this invention could be achieved by either a complete solid phase synthesis or a mixed technique whereby all or most of the peptide is synthesized by solid phase and the subsequent additions could be made in solution.

In the conventional peptide synthesis, the amino acids are  
15 sequentially coupled to achieve a complete peptide. The amino acids are conjugated to various protecting groups, such as BOC and Fmoc, hence also termed as BOC and Fmoc chemistries. The background information on peptide synthesis can be obtained by reference to "Solid phase peptide synthesis" Stewart & Young, W h Freeman Co. San Francisco, 1969 and  
20 Erikson and Merrifield, "The proteins" Vol. 2. (ed. Neurath & Hill), Academic press, New York. 1976).

In accordance with the present invention, there is provided a composition comprising an antagonist of a G protein-coupled receptor of prostaglandin E<sub>2</sub>, subtype EP<sub>4</sub> in association with a pharmacologically or  
25 physiologically or pharmaceutically acceptable carrier. The choice of the carrier is denoted by the specific application for which the said antagonist is used.

Numerous pharmaceutically acceptable carriers are known in the art and can be formulated with the composition of the invention using  
30 methods known in the art.

When the composition of the invention is used *in vitro*, it may be suspended in any acceptable carrier, such as physiological saline or any other buffer which is compatible with the particular cell or tissue system being investigated. *In vitro* formulations will thus be readily apparent to the artisan skilled in the art of conducting ligand binding assays using membranes or whole cells, physiological experiments using tissues.

The activity of the compounds of the present invention could be tested in a variety of assay systems and these are documented in the literature and is known to people versed in that art. For example. Cells in which EP4 receptor is expressed naturally, such as NIH3T3, or cDNAs are exogenously expressed using recombinant expression vectors, can be used to measure the efficacy and potency of antagonism of the compounds disclosed herein. Alternately, tissues known to express EP4 receptor, for example, saphenous vein, intestinal smooth muscle etc., can be used in organ bath assays to measure contraction/dilation or the tissue fragments or the membranes derived from the tissues could be incubated with radiolabelled ligands to measure ligand displacement, GTP binding and hydrolysis, second messenger (e. g. cAMP and inositol phosphates) synthesis. All these assays involve measuring one or more of the biochemical and physiological consequences of the signal transmission from said receptor, wherein said consequences are selected from the group consisting of GTP binding and hydrolysis by  $G_{\alpha}$  proteins, cyclic adenosine monophosphate synthesis, alterations in cell calcium, smooth muscle contraction or dilation, cell growth and/or differentiation, altered gene expression and smooth muscle contraction or dilation.

A more physiological way of assaying the activity of a compound listed herein is to introduce the compound in association with a suitable carrier in an animal using a dose range of 1  $\mu$ g-1000 mg/Kg body weight and a suitable route of administration (see below). The manipulations of the animals, routes of administration and dosing regimens are known to people versed in the art. For example, the present invention contains

description of the effects of certain compounds tested in rats, pigs and sheep and the methods are given in the examples.

When an antagonist of the invention is administered to a patient in need of a treatment, it may be formulated in any suitable formulation which will depend on number of factors including the particular condition to be treated, the age, the degree of disease or disorder etc. The inhibitors of the invention may be administered to a patient in one of the traditional modes (e.g., orally, parenterally, transdermally or transmucosally), in a sustained release formulation using a biodegradable biocompatible polymer, or by on-site delivery using micelles, gels and liposomes, or rectally (e.g., by suppository or enema) or nasally (e.g., by nasal spray). The appropriate pharmaceutically acceptable carrier will be evident to those skilled in the art and will depend in large part upon the route of administration. Formulations may also include those which render the inhibitor capable of crossing the blood brain barrier when administered by any other route. In addition, the inhibitors of the invention may be formulated so as to target specific types of cells. For example, it is now known in the art to encapsulate or otherwise formulate compounds such that they are directed to specific receptors on cells. Such formulations include antibody-tagging formulations, receptor-ligand binding formulations etc.

The inhibitors of the invention may also be administered by a peripheral route, or they may be administered systemically to the patient. "Peripheral administration" as used herein, denotes administration of a compound by any route other than direct administration to the brain. Thus, peripheral administration includes, but is not limited to, oral, nasopharyngeal, intraperitoneal, intramuscular and intravenous administration of any of the compounds of the invention.

Treatment regimes which are contemplated include a single dose or dosage which is administered hourly, daily, weekly or monthly, or yearly. Dosages may vary from 1  $\mu$ g to 1000 mg/kg of body weight of the



patient and will be in a form suitable for delivery of the compound. The route of administration may also vary depending upon the disorder to be treated.

5 In accordance with the above description, use of a pharmacological composition containing an EP4 antagonist in situations wherein administration of such a composition to a patient having a therapeutic need, results in increment in glomerular filtration and urine output. It is also envisaged that said formulation may be given to patients diagnosed with acute renal failure or end stage renal disease or a variety  
10 of glomerulopathies or nephropathies.

It is also mentioned that a pharmaceutical composition containing an antagonist of EP4 receptor may be administered to a patient or animal diagnosed with bone mineral loss, as seen in conditions of osteoporosis or dental disease or many immune and cancer-related  
15 diseases.

The use of a pharmaceutical preparation containing EP4 antagonist is also included in the present invention where a need to close the patent ductus arteriosus to avoid pulmonary hypertension in a premature infant.

20 The dose of an EP4 antagonist may be 1  $\mu$ g-1g / Kg of body weight of the patient or animal and administered by a peripheral route.

Another embodiment of the invention is that the peptide antagonists described in this invention could be used as a tool to validate the novel roles of prostaglandin E2 receptor subtype EP4 in tissues or in  
25 whole animals. For example, though EP<sub>4</sub> receptor is known to be present in glomerulus (Breyer, M.D., 1996; Morath, R., 1999) and ductus arteriosus (Bhattacharya, M. et al., 1999), the precise function of the receptor in these structures and in the physiology of the animal is not known. As described in the invention by using specific antagonists, inhibition of EP<sub>4</sub>  
30 receptor is shown to increase glomerular filtration and urine output in rats, close the ductus arteriosus in fetal sheep and decrease osteoclasogenesis

in human spleen cell co-cultures with osteoblasts. By providing such specific antagonists of the receptor with or without the knowledge of the natural ligand, persons versed in the art, can study the novel roles of prostaglandin E2 receptor subtype EP4 or other G protein-coupled  
5 receptors in tissues as well as in whole animals.

Another embodiment of the present invention is the use of the antagonist of EP4 receptor in a biochemical assay to validate the function of unknown ligands, physically identify and localize the said receptor in cells and tissues using such techniques as autoradiography, radioligand  
10 binding, radiosciintigraphy, positron emmision tomography etc. and the specific techniques vary with the experimental subject and are well known to the persons skilled in such an art. Therefore, a kit containing the antagonist of EP4 receptor attached with various labels, such as fluorochromes, radionucleides, immunoaffinity haptens, antibodies and  
15 other affinity tags, is also included in the present invention.

### **Preparation of inhibitors and materials**

#### Chemical synthesis of peptides and peptidomimetics:

We have synthesized using F-moc chemistry and solid phase  
20 Merrifield method several peptides and peptidomimetics. The purity of these peptides was assessed by HPLC and mass spectroscopy. The general methods are understood by referring to the following treatises: "Solid phase peptide synthesis" Stewart & Young, W h Freeman Co. San Francisco, 1969 and Erikson and Merrifield, "The proteins" Vol. 2. (ed.  
25 Neurath & Hill), Academic press, New York. 1976).

Unless otherwise specified, all peptides and peptidomimetics contained D-amino acids. For *in vitro* experiments, peptides were weighed and dissolved in dimethyl sulfoxide at 10 mM and for *in vivo* experiments, in sterile saline at the indicated concentrations. The solutions were made  
30 freshly and discarded after use.

Expression of EP<sub>4</sub> cDNA in HEK 293 cells:

Human EP<sub>4</sub> coding region was amplified from Jurkat cells. using RT-PCR. Briefly, total RNA was extracted from Jurkat cells (~10<sup>7</sup> cells) using the Trizol™ reagent (Life technologies, Burlington, ON). The purity and the quantity of the RNA were assessed by determining the absorption at 260 and 280 nm. An aliquot of the RNA was reverse transcribed using Superscript II reverse transcriptase (Life technologies, Burlington, ON) (200 U) and 100 µM oligo(dT)<sub>12-18</sub> in the reaction buffer (50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM MgCl<sub>2</sub>, 10 mM DTT) for 1 h at 42°C. A portion of the cDNA (corresponding to 1 µg of RNA) was amplified by PCR using 10 µM each of primers, EP4.1 (5' ATC ATG TCC ACT TCC GGG GTC 3' SEQ ID NO:10) and EP4.2 (5' CTA TTA TAT ACA TTT TTC TGA TAA GTT CAG 3' SEQ ID NO:11) and 2 U Vent™ polymerase (New England Biolabs, Mississauga, ON) in Thermopol™ (New England Biolabs, Mississauga, ON) reaction buffer (20 mM Tris-HCl pH 8.8, 10 mM KCl, 10 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 2 mM MgSO<sub>4</sub>, 0.1% Triton X-100, 0.2 mM dNTPs and 5% DMSO) for 30 cycles (94°C-1 min; 55°C-1 min; 72°C-1.5 min). The DNA fragment was purified by agarose gel electrophoresis, phosphorylated by T4 polynucleotide kinase and cloned into Hinc II site of pGEM-3 (Promega, Madison, WI) by blunt-end ligation using standard molecular biology methods (Maniatis, T. et al. 1989. *Molecular cloning: a laboratory manual*. Cold Spring Harbor Press. New York). The sequence of the EP<sub>4</sub> cDNA was determined by sequencing. EP<sub>4</sub> coding region (Hind III-Xba I fragment) was cloned into a eukaryotic expression vector, pRC-CMV (Invitrogen, San Diego, CA) to give EP<sub>4</sub>/RC-CMV plasmid.

HEK293 cells (2x10<sup>5</sup> cells/well of a 6-well plate) were transfected with EP<sub>4</sub>/RC-CMV using lipofectamine™ (Life technologies, Burlington, ON) according to the instructions supplied by the manufacturer. Briefly, 2 µg of plasmid was complexed with 4 µl of lipid in OPTI-MEM medium for 30 min and the DNA-lipid complexes were added to the cells and left for 6 h at 37°C. Later, the medium was replaced with DMEM containing 10%

FBS. After two days, the cells were split into DMEM medium and the antibiotic-resistant cells were selected with 1 mg/ml G418 (Life technologies, Burlington, ON). After 10-12 days in selection, G418-resistant colonies were pooled and propagated. EP<sub>4</sub> receptor expression in the pooled population of cells was confirmed by radioligand binding and cAMP synthesis in response to PGE<sub>2</sub>.

The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.

#### Example I

##### **Basal and PGE<sub>2</sub>-stimulated cyclic adenosine monophosphate levels in response to PHG 213**

Basal cAMP levels in EP<sub>4</sub>/293 cells were increased compared to the parent HEK293 cells in the presence of isobutyl methylxanthine (IBMX), a phosphodiesterase inhibitor; this is attributed mainly to the increased basal activity of adenylate cyclase due to the over-expression of EP<sub>4</sub> receptor. The efficacy of the peptide inhibitors was tested on the basal levels of cAMP in these cells.

Method: EP<sub>4</sub>/293 cells were seeded at 5x10<sup>5</sup> cells/well in 6-well plates and next day, treated with 100 μM of IBMX for 1 h in the presence or absence of PHG213 (100 μM). The medium was removed and 0.3 ml of ethanol was added to precipitate the protein and extract cAMP. Protein-free supernatants obtained after centrifugation were lyophilized. The residues were resuspended in binding buffer and the cAMP levels were determined using a commercial kit.

The results are presented in Table 1 below. The cells were treated with PHG213 (SEQ ID NO:1) (100 μM) in the presence of 100 μM IBMX for 1h. Forskolin and PGE<sub>2</sub> were added for only 15 min. Data are averages of four replicates. Table 1 illustrates the alterations in basal and PGE<sub>2</sub>-stimulated cyclic adenosine monophosphate levels in response to PHG 213.

**Table 1****Effect of PHG213 on basal cAMP levels in EP<sub>4</sub>/293 cells**

peptide	CAMP (pmol/ml/10 <sup>5</sup> cells)	% inhibition
vehicle	69.9	-
PHG 213	27.5	60.7
PGE <sub>2</sub> (1 μM)	>270	-
FSK (100 μM)	>270	-

Basal cAMP levels increased over time in the presence of IBMX  
5 in EP<sub>4</sub>/293 cells. PHG213 potently decreased the accumulation of cAMP.  
Addition of PGE<sub>2</sub> (1 μM) or forskolin (100 μM), an adenylate cyclase  
activator, increased cAMP levels suggesting that the EP<sub>4</sub> signaling  
pathway consisting of adenylate cyclase was fully active in these cells.  
Thus it appeared that PHG213 is a potent inhibitor of basal activity of EP<sub>4</sub>  
10 receptor in these cells.

**Example II****Effects of PHG213 and its peptidomimetic variants on PGE<sub>2</sub>-induced  
dilation of saphenous vein strips in organ bath assay**

15

In order to produce a potent antagonist, various modifications of  
the sequence of 213 (SEQ ID NO:1) were designed and synthesized using  
F-moc chemistry. Peptides and peptidomimetics were purified using HPLC.  
These include 213.2: (SEQ ID NO:2); 213.4: (SEQ ID NO:3); 213.6: (SEQ  
20 ID NO:4); 213.7: (SEQ ID NO:5); 213.9: (SEQ ID NO:6); 213.15: (SEQ ID  
NO:7); 213.16: (SEQ ID NO:8); 213.17: (SEQ ID NO:9).

*Animals.* Yorkshire piglets (2-4 days old) were used in this study,  
according to a protocol approved by the Animal Care Committee of the  
Research Centre of Ste-Justine Hospital. Briefly, animals were

anesthetized with 1.5% halothane and the lower external saphenous veins removed and placed in cold Krebs buffer (pH 7.4) of the following composition (mM): NaCl 120, KCl 4.5, CaCl<sub>2</sub> 2.5, MgSO<sub>4</sub> 1.0, NaHCO<sub>3</sub> 27, KH<sub>2</sub>PO<sub>4</sub> 1.0, glucose 10, to which 1.5 U/ml heparin was added.

5           *Organ bath assay.* The saphenous veins were cleaned of extraneous tissue and cut into 4 mm rings that were placed in individual jacketed organ baths (15 ml; Radnoti Glass, Monrovia, CA) containing Krebs buffer and maintained at 37°C. The solution was bubbled with a mixture of 95%O<sub>2</sub> - 5% CO<sub>2</sub>. In each experiment, 8 rings were used (4 from  
10 each saphenous vein) and were equilibrated for 60 min under 2.0 gr passive tension, with frequent washing and tension adjustment. Tension was measured by force-displacement transducers and was recorded on a computerized data acquisition system using the Work Bench software (both from Kent Scientific, Litchfield, CT).

15           *Experimental protocol.* In a first set of experiments, the relative distribution of dilatory EP receptor subtypes was ascertained using a combination of EP receptor agonists and antagonists. The vasodilatory response of the lower external saphenous veins to PGE<sub>2</sub> appears to result from the stimulation of 30% EP<sub>2</sub> and 70% EP<sub>4</sub>. Tissues were initially  
20 challenged with 2 x 10<sup>-7</sup> U46619 which induced a 1.5 to 2.0 gr increase in tension. Rings which did not respond were discarded. When the response to U46619 reached a steady state, agents were added. When no response to the agents were observed, a period of 10 minutes was allowed to insure proper distribution of the agents in the tissue. Dose-  
25 response curves to PGE<sub>2</sub> (10<sup>-10</sup> - 10<sup>-6</sup> M) were then obtained in the presence of absence of each of the tested drugs.

The results of the experiments were shown in Table II below. The results are average of 2-8 experiments. The results are tabulated as percent reversal of 1 μM PGE<sub>2</sub>-induced constriction in the presence of 1  
30 μM peptides. The peptides shown here contain productive and effective substitutions in the parent peptide PHG 213 (SEQ ID NO:1)

**Table 2**

**Effects of peptidomimetic derivatives of PHG213 on PGE<sub>2</sub>-induced vasorelaxation in saphenous vein of piglet**

SEQ ID NO	% blockade of PGE <sub>2</sub> induced vasodilation
1	50.0
2	35.0
3	20.0
4	60.0
5	60.0
6	30.0
7	65.5
8	64.5
9	34.0

5

**Example III****Effects of PHG213 on ocular perfusion rates in porcine eye model**

In order to test the efficacy of PHG213 (SEQ ID NO:1) on EP<sub>4</sub> receptor function, an ex vivo assay of vasomotricity of porcine choroid was used. The dilatory response to PGE<sub>2</sub> in this vascular bed was previously shown to be mediated by EP<sub>4</sub> receptor (Abran, D. et al. 1997. *Am. J. Physiol.* 272: R995-1001).

*Method:* The method as described in detail by Abran et al. (1997) was followed exactly. A vortex vein from the eye of a newborn pig was catheterized with a 27-gauge needle and perfused with Kreb's solution until perfusion pressure was stable. The vasculature was first constricted with a thromboxane mimetic, U46619 (1  $\mu$ M), and then PGE<sub>2</sub> was infused at 1  $\mu$ M. Once the reversal of constriction reached a plateau, then PHG213 was infused at 100  $\mu$ M and the perfusion pressure was recorded.

The results are shown in Fig. 1. Positive values of perfusion pressure indicate constriction whereas negative values indicate dilation of the vasculature. PGE<sub>2</sub> reversed the constriction produced by U46619. Perfusion of PHG213 blocked this dilatory effect of PGE<sub>2</sub> completely. Since  
5 it is known that the dilatory effects of PGE<sub>2</sub> are predominantly mediated by EP<sub>4</sub> receptor in choroid of the newborn pig, PHG 213 antagonized the actions of EP<sub>4</sub> receptor and blocked the dilation produced by this receptor.

#### Example IV

##### **Effects of PHG213 on glomerular filtration rate and urinary volume in 10 normal rats**

EP<sub>4</sub> receptor is localized in glomerulus and possibly, in the collecting duct and we hypothesized that EP<sub>4</sub> antagonist may increase glomerular filtration rate. For this purpose, we have developed and tested PHG 213 (SEQ ID NO:1) in an *in vivo* rat model.

15 *Method:* Sprague-Dawley adult rats (~250 g) were anesthetized with 50 mg/kg pentobarbitone. Left jugular vein (for infusion) and left carotid artery (for measuring blood pressure) were catheterized and another catheter was placed at the tip of the bladder for collecting urine. Infusion of [<sup>3</sup>H]-inulin in saline (2 µCi/Kg/h) was started and continued for 2  
20 h to stabilize the system. Urine collection was exactly for 20 min and at 10 min mark, 0.1 ml of blood was withdrawn into heparinized tubes. Blood was centrifuged and radioactivity in plasma was counted. After 10 min and 30 min (30 min and 60 min since the start of the previous urine collection), the process was repeated. The antagonist, PHG 213, was infused in saline  
25 i.v. at 6 µmol/Kg/h for one hour before the start of first urine collection. Urinary volume (UV) is calculated and expressed as µl of urine/h corrected for the weight of the animal. GFR was calculated as the ratio of urinary inulin concentration to plasma inulin concentration corrected for the volume of the urine and the weight of the animal.

30 The results are shown in Fig. 2. The mean blood pressure was not significantly altered by the peptide. Urinary flow rate (UV) dramatically



increased by 2.3 fold and glomerular filtration rate(GFR) increased by 157%. These alterations in urine output are indications of the EP<sub>4</sub> receptor antagonist effects in the glomerulus where it increased filtration and in collecting duct where it inhibited re-absorption, thus resulting in higher urine out put.

#### **Example V**

##### **Effects of PHG213 on glomerular filtration rate and urinary volume in diabetic rats**

Decreased glomerular function is a hallmark of end-stage renal disease (ESRD) and drugs that improve GFR will of immense therapeutic value in delaying the progression of the disease. In order to find if EP<sub>4</sub> antagonists could increase glomerular function, we have used the streptozotocin-induced diabetic rat as a model.

*Method:* Sprague-Dawley adult rats (~250 g) were injected i.p. with streptozotocin (45-50 mg/Kg) and two days later, the urine was tested for glucose and proteinuria. Two weeks later, the rats that tested positive for both markers were chosen to test the effects of PHG 213 (SEQ ID NO:1) on GFR and UV using a method described above.

The results are shown in Fig. 3. Systemic infusion of EP4.3 increased, in accordance with its postulated inhibition of PGE<sub>2</sub> effects via EP<sub>4</sub> receptor, both GFR and UV. Mean blood pressure was not significantly altered in these animals, suggesting that EP<sub>4</sub> receptor contributes minimally to blood pressure homeostasis which is a desirable attribute of the drug. These results suggest that in diabetic animals similar to the normal, EP<sub>4</sub> receptor is expressed and regulates glomerular filtration.

#### **Example VI**

##### **Effects of PHG213 on the ductus arteriosus of fetal sheep**

Pregnant ewes (129-140 days of gestation) was anesthetized with ketamine (30 mg/Kg i.v.), a caesarian section was performed and the

fetus exteriorized. To mimic fetal respiratory conditions, the head of the fetus was submerged in a glove filled with saline. Femoral and jugular veins were catheterized for systemic blood pressure measurements and drug infusions respectively. Ductus arteriosus (DA) diameter was measured using Doppler echocardiography as described before (Teyssier, G. et al. 1989. *J. Cardiovascular Technol.* 8: 259-266). Echocardiographic measurements were performed with an Acuson 128 XP/10C real time ultrasound imaging system using 7.5 or 5-MHz transducers duplexed with a range-gated Doppler. Doppler signals were filtered by a 100-Hz high-pass filter. The DA was visualized through a left second intercostal parasternal approach. After the drugs were injected, measurements of DA diameter were repeated 3 times at 5 min intervals for the next 20-25 min.

The results are shown in Fig. 4. DA was unchanged for 40 min during the stabilization period. Within minutes following infusion of PHG213 (SEQ ID NO:1) (2 mg of bolus followed by 1 mg/Kg infusion over 15 min), DA started to constrict and continued for another 15 min and was irreversible. PHG213, a peptide antagonist of EP4 receptor, blocked the dilatory action of the receptor which is responsible for maintaining the ductus open in the fetus.

#### Example VII

##### **Effects of PHG213 on osteoclasogenesis in cocultures of human spleen cells and SaOS-2 immortalized and fixed human osteoblasts**

Osteoclasts attach to bone and cause resorption or bone loss. It is therapeutically advantageous to inhibit the increment in the number of osteoclasts (osteoclast differentiation) in osteoporosis in order to prevent the bone loss. In order to test the efficacy of PHG213 (SEQ ID NO 1) on osteoclast differentiation, a coculture system of human fetal spleen cells and human osteoblast cells was used.

*Method:* SaOs-2 cells (immortalized cell line of human osteoblasts) were grown for four days in 24-well plates in alpha-MEM

medium containing 10% fetal calf serum, vitamin D3 ( $10^{-7}$ ). Confluent SaOs-2 cells were fixed in 1% paraformaldehyde (M) and dexamethasone ( $10^{-8}$ M in phosphate-buffered saline (PBS) for 8 min. The cells were rinsed with PBS 4 times and alpha-MEM containing 10% fetal calf serum and vitamin D3 ( $10^{-7}$  M) was added.

Two days before, spleens from human abortuses were cut into small pieces and triturated several times to release the cells. The spleen cells were cultured in alpha-MEM containing 10% fetal calf serum for 2 days. Spleen cells were trypsinized, rinsed once in PBS and counted using a coulter counter. An aliquot of spleen cells ( $10^5$  cells/well) were placed over the monolayer of fixed SaOs-2 cells for 2 h, after which PHG213 (100  $\mu$ M) was added. Three days later, the cells were fixed in 4% paraformaldehyde in PBS, rinsed with water and tartrate-resistant alkaline phosphatase (TRAP) was stained using a commercial kit (Sigma, St. Louis, MO). TRAP-positive cells were viewed under a microscope and counted.


The results of the experiments were shown in Fig. 5. Data are average of several experiments ( $n = 10$ ). Addition of PHG213 reduced the number of TRAP-positive cells (osteoclasts) by half in this human cell coculture system. This is the first time that a specific inhibitor of human EP4 receptor, PHG213, prevented the differentiation of progenitor cells in spleen to become osteoclasts, thus the inhibition of EP4 receptor has potential application in treating osteoporosis which is characterized by excess bone loss mediated by osteoclasts.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential

features hereinbefore set forth, and as follows in the scope of the appended claims.

**WHAT IS CLAIMED IS:**

1. A peptide of the following formula:



wherein,

Y1 is attached to the N-terminus of the peptide and selected from the group consisting of a proton, a sequence of 1-3 amino acids, or a blocking group such as a carbamate group, an acyl group composed of a hydrophobic moiety such as cyclohexyl, phenyl, benzyl, short chain linear and branched alkyl groups of 1-8 carbons;

R1 is selected from the group consisting of Val, Ala, Ile, Gln, Leu, or Arg;

R2 is selected from the group consisting of Ala, Ile, Phe, Arg, or Leu;

R3 is selected from the group consisting of Pro, Thr, Ser, Tyr, Leu, or Val;

R4 is selected from the group consisting of Met, Ala, Gly, Ser, Val, or Ile;

R5 is selected from the group consisting of Thr, Pro, Tyr, Leu, Gly, or Gln;

R6 is selected from the group consisting of is Val, Cys, Ile, Gly, Glu, or Ser;


R7 is selected from the group consisting of is Pro, Val, Cys, Leu, Glu or Asn;

R8 is selected from the group consisting of is Ser, Leu, Thr, or Ala;

Z1 is attached to the carboxy-terminus of the peptide and selected from the group consisting of proton,  $NH_2$ , 1-3 amino acids as well as arylalkyl amines and aliphatic amines possessing short chain linear and branched alkyl groups of 1 to 8 carbons.

2. The peptide of claim 1, wherein said peptide is capable of inhibiting at least one functional consequence of prostaglandin E2 receptor subtype EP4.

3. A compound of the following structure,



wherein:

Y2 is attached to the N-terminus of the peptide and selected from the group consisting of a proton, a sequence of 1-3 amino acids, or a blocking group such as a carbamate group, an acyl group composed of a hydrophobic moiety such as cyclohexyl, phenyl, benzyl, short chain linear and branched alkyl groups of 1-8 carbons;

AA1 is selected from the group consisting of no residue, Ile, Leu, Phe and related alpha-amino acids with hydrophobic side-chains, arylalkyl amines;

AA2 is selected from the group consisting of no residue, Leu, Ile, Phe and related alpha-amino acids with hydrophobic side-chains, arylalkyl amines;

AA3 is selected from the group consisting of no residue, Ala, Ser, Thr and other related alpha amino acids with side chains containing hydroxyl or H-bond forming groups;

AA4 is selected from the group consisting of Ser, Thr, and related alpha-amino acids with side chains containing hydroxyl groups or H-bond forming groups;

AA5 is selected from the group consisting of Ala, Tyr, Phe, and other related alpha amino acids with side chains containing benzoyl, phenolic groups and arylalkyl amines;

AA6 is selected from the group consisting of Glu, Gln, Asp, Asn, and related alpha amino acids with side chains containing charged or H-bond accepting groups ;

AA7 is selected from the group consisting of no residue, Ala, Cys, Ser, Thr and related alpha-amino acids with side chains containing sulfhydryl, hydroxyl groups;

AA8 is selected from the group consisting of no residue, Ile, Ala, Leu, Phe and other alpha-amino acids with hydrophobic side-chains, arylalkyl amines (benzylamine, phenylethylamine, phenylpropylamine), and aliphatic amines with short chain linear and branched alkyl groups of 1 to 8 carbons;

Z2 is attached to the carboxy-terminus of the peptide and selected from the group consisting of proton,  $\text{NH}_2$ , 1-3 amino acids, arylalkyl amines, and

aliphatic amines with short chain linear and branched alkyl groups of 1 to 8 carbons.

4. A compound of claim 3, wherein said compound is capable of inhibiting at least one functional consequence of prostaglandin E2 receptor subtype EP4.

5. The compound of claim 4, wherein the said compound is selected from a group consisting of IFTSYECL (SEQ ID NO:1); IFASYECL (SEQ ID NO:2); IFTSAECL (SEQ ID NO:3); IFTSYEAL (SEQ ID NO:4); ILASYECL (SEQ ID NO:5); IFTSYDCL (SEQ ID NO:6); (4-biphenyl alanine) TSYEAL (SEQ ID NO:7); (diphenyl alanine) TSYEAL (SEQ ID NO:8); (homophenyl alanine) TSYEAL (SEQ ID NO:9).

6. A composition containing the compound of any of claims 3 to 5 in association with a suitable pharmaceutical carrier.

7. Use of a compound of any of claims 3 to 5 to improve the glomerular filtration and/or urine output of a patient in need of such a treatment.

8. A method of improving glomerular filtration and/or urine output of a patient comprising the step of administering to a patient in need of such a treatment a therapeutically effective amount of a compound of any one of claims 3 to 5.

9. A pharmaceutical composition comprising a compound of any one of claims 3 to 5 to be administered to a patient by a peripheral route in the dose range of about 1  $\mu$ g to about 1000 mg, wherein the patient is diagnosed with end stage renal disease or acute renal failure.

10. A method for the treatment of end stage renal disease or acute renal failure in a patient comprising the step of administering to said patient a therapeutically effective amount of a compound of any one of claims 3 to 5.
11. Use of a compound of any of claims 3 to 5 to close ductus arteriosus (DA) in a premature infant patient.
12. A pharmaceutical composition comprising a compound of any one of claims 3 to 5, to be administered to a patient by a peripheral route in the dose range of 1  $\mu$ g-1000 mg, wherein the said patient is diagnosed with patent ductus arteriosus.
13. A method of closing ductus arteriosus (DA) in a premature infant patient comprising the step of administering to said patient in need of such a treatment a therapeutically effective amount of antagonist of any one of claims 3 to 5.
14. The use of a compound of in any of claims 3 to 5 in an assay comprising the steps of:
- a) culturing cells or tissues expressing said receptor naturally or recombinantly;
  - b) treating said cultured cells or tissues with a quantity of an compound of any one of claims 3 to 5 in the presence or absence of a known concentration of an agonist of said receptor;
  - c) measuring one or more of the biochemical and physiological consequences of the signal transmission from said receptor, wherein said consequences are selected from the group consisting of GTP binding and hydrolysis by  $G_{\alpha}$  proteins, cyclic adenosine monophosphate synthesis, alterations in cell calcium, smooth muscle contraction or dilation, cell growth and/or



differentiation, altered gene expression and smooth muscle contraction or dilation.

15. An assay kit containing a compound of any of claims 3 to 5.



16. Use of a compound of any one of claims 3 to 5 to prevent bone mineral loss in a patient comprising the step of administering to said patient in need of such a treatment a therapeutically effective amount of the said compound.

17. A pharmaceutical composition comprising a compound of any one of claims 3 to 5, to be administered to a patient by a peripheral route in the dose range of about 1  $\mu$ g to about 1000 mg, where in the said patient is diagnosed with having symptoms of osteoporosis or dental disease.

18. A method of treating bone mineral loss in a patient comprising the step of administering to said patient in need of such a treatment a therapeutically effective amount of compound of any one of claims 3 to 5.

19. A method for the treatment of end stage renal disease or acute renal failure in a patient comprising the step of administering to said patient a therapeutically effective amount of a compound of any one of claims 3 to 5.

1/3



2/3




FIG. 3





FIG. 4

3/3

FIG. 5

## SEQUENCE LISTING

<110> HOPITAL SAINTE-JUSTINE  
PERI, Krishna G.  
CHEMTOB, Sylvain

<120> METHOD OF TREATING ABNORMALITIES IN  
GLOMERULAR FILTRATION, PATENT DUCTUS ARTERIOSUS AND  
OSTEOPOROSIS

<130> 12667-20PCT FC

<150> US 09/455,483

<151> 1999-12-06

<160> 11

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide inhibitor of prostaglandin E2 receptor  
subtype EP4

<400> 1

Ile Phe Thr Ser Tyr Glu Cys Leu  
1 5

<210> 2

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide inhibitor of prostaglandin E2 receptor  
subtype EP4

<400> 2

Ile Phe Ala Ser Tyr Glu Cys Leu  
1 5

<210> 3

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide inhibitor of prostaglandin E2 receptor  
subtype EP4

<400> 3

Ile Phe Thr Ser Ala Glu Cys Leu  
1 5

<210> 4  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Peptide inhibitor of prostaglandin E2 receptor  
subtype EP4

<400> 4

Ile Phe Thr Ser Tyr Glu Ala Leu  
1 5

<210> 5  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Peptide inhibitor of prostaglandin E2 receptor  
subtype EP4

<400> 5

Ile Leu Ala Ser Tyr Glu Cys Leu  
1 5

<210> 6  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Peptide inhibitor of prostaglandin E2 receptor  
subtype EP4

<400> 6

Ile Phe Thr Ser Tyr Asp Cys Leu  
1 5

<210> 7  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Peptide inhibitor of prostaglandin E2 receptor  
subtype EP4

<221> MOD\_RES  
<222> (1)...(1)  
<223> 4-biphenyl alanine

<400> 7

Xaa Thr Ser Tyr Glu Ala Leu  
1 5

<210> 8  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Peptide inhibitor of prostaglandin E2 receptor  
subtype EP4

<221> MOD\_RES  
<222> (1)...(1)  
<223> Diphenyl alanine

<400> 8  
Xaa Thr Ser Tyr Glu Ala Leu  
1 5

<210> 9  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Peptide inhibitor of prostaglandin E2 receptor  
subtype EP4

<221> MOD\_RES  
<222> (1)...(1)  
<223> Homophenyl alanine

<400> 9  
Xaa Thr Ser Tyr Glu Ala Leu  
1 5

<210> 10  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> cDNA primer

<400> 10  
atcatgtcca cttccggggt c

<210> 11  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> cDNA primer

WO 01/42281

4/4

PCT/CA00/01445

<400> 11  
ctattatata catttttctg ataagttcag

30



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01445

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K7/04 C07K7/06 A61K38/08

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BIOSIS, EMBASE, WPI Data, STRAND

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 18236 A (UNIV NEW YORK) 22 May 1997 (1997-05-22) page 104; example 164 ---	1
X	WO 95 29193 A (US HEALTH) 2 November 1995 (1995-11-02) page 140; example 67 page 138; example 58 ---	1
X	WO 97 34621 A (CYTEL CORP) 25 September 1997 (1997-09-25) page 29; example 4 ---	1
X	WO 95 11987 A (INCYTE PHARMA INC ; SCOTT RANDY W (US); BRAXTON SCOTT M (US)) 4 May 1995 (1995-05-04) page 106, line 17; claim 5 --- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

9 March 2001

Date of mailing of the international search report

02/04/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Deffner, C-A

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 00/01445

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 20127 A (CYTEL CORP) 15 September 1994 (1994-09-15) *peptide VLVGGVLAAL* page 108	1
X	WO 99 55849 A (COULSON BARBARA SUE ; HONEYMAN MARGO CAROLE (AU); INST MEDICAL W &) 4 November 1999 (1999-11-04) *peptides IIVILSPLLN, IIVILSPLSN, IIVILSPLLN, IIVILSPLSN page 26	1
X	WO 98 26070 A (TAM CHERK SHING ; GENSCI REGENERATION SCIENCES I (CA)) 18 June 1998 (1998-06-18) *see sequence no.36*	3
X	WO 97 12624 A (DEFEO JONES DEBORAH ; FENG DONG MEI (US); OLIFF ALLEN I (US); GARSK) 10 April 1997 (1997-04-10) *see sequences no. 83, 88, 89, 94, 120, 121, 123, 193	3
X	WO 96 06856 A (WEBBER ROBERT) 7 March 1996 (1996-03-07) figure 4B	3
X	SCHRAMM H.J. ET AL.: "The Inhibition of Human Immunodeficiency Virus Proteases by 'Interface Peptides'" ANTIVIRAL RES., vol. 30, no. 2,3, 1996, pages 155-70, XP002162509 *peptide VSYECG* figure 1	3
A	WO 96 19233 A (DEMOPULOS GREGORY A ; HERZ JEFFREY M (US); OMEROS MED SYS INC (US);) 27 June 1996 (1996-06-27) page 23, line 13 - line 21	1,3
A	ISE H.: "Activation of the Prostaglandin EP4- Receptor Subtype is Highly Coupled to Inhibition of N- Formyl- Methionyl- Leucyl- Phenylalanine Stimulated Rat Neutrophil Aggregation" PROSTAGLANDINS, LEUKOTRIENS AND ESSENTIAL FATTY ACIDS, vol. 58, 1998, pages 77-84, XP002162510 *see compound AH2384B*	1,3

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/01445

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9718236 A	22-05-1997	US 5877155 A CN 1202175 A EP 0876396 A	02-03-1999 16-12-1998 11-11-1998
WO 9529193 A	02-11-1995	US 5874560 A US 5844075 A AU 706443 B AU 2395895 A CA 2188432 A EP 0756604 A FI 964235 A JP 10505481 T US 5994523 A	23-02-1999 01-12-1998 17-06-1999 16-11-1995 02-11-1995 05-02-1997 20-12-1996 02-06-1998 30-11-1999
WO 9734621 A	25-09-1997	AU 2658897 A BR 9708220 A CA 2248667 A CN 1218406 A EP 0907370 A	10-10-1997 04-01-2000 25-09-1997 02-06-1999 14-04-1999
WO 9511987 A	04-05-1995	AU 685187 B AU 8076994 A EP 0730660 A JP 9504174 T US 5766897 A	15-01-1998 22-05-1995 11-09-1996 28-04-1997 16-06-1998
WO 9420127 A	15-09-1994	AU 6359494 A AU 6597998 A BR 9406652 A CA 2157510 A CN 1118572 A EP 0703783 A JP 8507525 T NZ 263050 A SG 49008 A	26-09-1994 02-07-1998 10-09-1996 15-09-1994 13-03-1996 03-04-1996 13-08-1996 24-11-1997 18-05-1998
WO 9955849 A	04-11-1999	AU 3399999 A	16-11-1999
WO 9826070 A	18-06-1998	US 6117839 A AU 5471098 A EP 0946728 A	12-09-2000 03-07-1998 06-10-1999
WO 9712624 A	10-04-1997	US 5866679 A AU 7203496 A CA 2233272 A EP 0853483 A JP 10512588 T US 6130204 A	02-02-1999 28-04-1997 10-04-1997 22-07-1998 02-12-1998 10-10-2000
WO 9606856 A	07-03-1996	NONE	
WO 9619233 A	27-06-1996	AU 4467396 A BR 9509985 A CA 2206119 A CN 1175213 A EP 0799051 A JP 10510540 T NO 972687 A	10-07-1996 03-11-1998 27-06-1996 04-03-1998 08-10-1997 13-10-1998 07-08-1997

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In tional Application No

PCT/CA 00/01445

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9619233 A		US 6056715 A	02-05-2000
		US 5820583 A	13-10-1998
		US 5800385 A	01-09-1998
		US 5860950 A	19-01-1999
		US 5858017 A	12-01-1999